021-51111890
购物车（）
sales@molnova.cn
DRF-1042
CAS No. 200619-13-2
DRF-1042 ( —— )
产品货号. M33344 CAS No. 200619-13-2
DRF-1042 是一种具有口服活性的喜树碱类似物，具有抑制 DNA 拓扑异构酶 I (DNA topoisomerase I) 的作用。DRF-1042 对一组人癌细胞株，包括多药耐药 (MDR)表型，显示出良好的抗癌活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥629 | 有现货 |
|
| 10MG | ￥1017 | 有现货 |
|
| 25MG | ￥2037 | 有现货 |
|
| 50MG | ￥3274 | 有现货 |
|
| 100MG | ￥4428 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥692 | 有现货 |
|
生物学信息
-
产品名称DRF-1042
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述DRF-1042 是一种具有口服活性的喜树碱类似物，具有抑制 DNA 拓扑异构酶 I (DNA topoisomerase I) 的作用。DRF-1042 对一组人癌细胞株，包括多药耐药 (MDR)表型，显示出良好的抗癌活性。
-
产品描述DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype.
-
体外实验DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.
-
体内实验In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Topoisomerase
-
受体Topoisomerase
-
研究领域——
-
适应症——
化学信息
-
CAS Number200619-13-2
-
分子量408.4
-
分子式C22H20N2O6
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 50 mg/mL (122.43 mM; 超声助溶 )
-
SMILESCC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3C(OCCO)n1c2=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.?
